MarketPulse

obesity market

4 articles
BenzingaBenzinga··Vandana Singh

India's Generic Semaglutide Flood Slashes Ozempic Costs by 70%, Reshaping Global Obesity Market

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.
NVOHIMSRDYweight loss drugsobesity market
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Viking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs
BenzingaBenzinga··Erica Kollmann

Novo Nordisk Stock Drops 16% After CagriSema Misses Efficacy Target

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.
LLYNVOclinical trialobesity market